Spyre Therapeutics, Inc. SYRE Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s short-term investments?
- Spyre Therapeutics, Inc. (SYRE) reported short-term investments of $644.28M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s short-term investments changed year-over-year?
- Spyre Therapeutics, Inc.'s short-term investments increased by 24.8% year-over-year, from $516.33M to $644.28M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s short-term investments?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s short-term investments has grown at a 64.2% compound annual growth rate (CAGR), from $56.18M to $670.81M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.